{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-198392","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.589259+00:00","generated_at":"2026-05-31T10:06:27.249271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025","bullets":["Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.","Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.","TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.","High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-198392","json":"https://secwatch.observer/filing/0001193125-24-198392.json","markdown":"https://secwatch.observer/filing/0001193125-24-198392.md","text":"https://secwatch.observer/filing/0001193125-24-198392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/0001193125-24-198392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/d760391d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:06:27.249271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}